Trial Profile
An open-label, 3-parallel panel, 3-period, pharmacokinetic interactions and tolerability study between elbasvir MK-8742 and ritonavir-boosted HIV protease inhibitors (atazanavir, lopinavir, darunavir) in healthy volunteers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2015
Price :
$35
*
At a glance
- Drugs Elbasvir (Primary) ; Atazanavir; Darunavir; Lopinavir; Ritonavir
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- 19 Dec 2015 New trial record